首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

2078219

生物標記市場：按產品類型、應用、適應症、最終用戶和地區分類的市場規模、佔有率、前景和機會分析（2025-2032 年）

Biomarkers Market, By Product Type, By Application, By Disease Indication, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，生物標記市場規模將達到927.5億美元，到2033年將達到2,292.4億美元。預計從2026年到2033年，其複合年成長率將達到13.8%。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	927.5億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	13.80%	預計金額（2033 年）	2292.4億美元

生物標記是一種能夠定量描述生物狀態或狀況的指標。生物標記檢測和研究通常使用血液、尿液或軟組織樣本，以探討典型的生物過程、病理過程或對治療性介入的藥理反應。生物標記在許多科學領域都有應用。目前市面上常用的兩種生物標記產品是「生物標記檢測套組」和「生物標記分析儀」。醫療產業使用的生物標記也屬於相對較新的臨床工具集，並按臨床應用進行分類。

市場動態

預計市場參與者新產品的推出將推動預測期內的市場成長。例如，2021年4月19日，全球生技公司安進（Amgen）宣布啟動「生物標記輔助計畫」（Biomarker Assist），旨在為轉移性（IV期）非小細胞肺癌（NSCLC）患者提供生物標記檢測服務。安進致力於利用科學和創新將新概念和醫學發現轉化為治療方案，造福重症疾病患者。在確診時進行生物標記檢測是指導患者選擇合適治療方案的關鍵第一步。符合資格的患者可透過「生物標記輔助計畫」享有生物標記檢測折扣。

此外，2022年2月28日，美國國立衛生研究院基金會（NIH）生物標記聯盟啟動了舉措計畫。該計劃旨在尋找最有效的血液檢測方法，用於評估對早期發現罕見神經退化性疾病至關重要的蛋白質。這項名為「神經絲蛋白作為遺傳性額顳葉型失智症（FTD）神經退化的液體生物標記」的研究將證明，針對這種名為神經絲蛋白的一種或多種血液檢測方法，可用於識別因遺傳和家族因素而存在額顳葉型失智症（FTD）風險的個體。這標誌著在開發可靠、經濟且非侵入性的方法來更準確地預測額顳葉型失智症（FTD）方面邁出了至關重要的第一步。此外，高風險族群將有機會參與新療法的臨床試驗，最終促進治療方法的開發。

本報告的主要特點

本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
本節根據公司概況、產品系列、主要趨勢、財務表現和策略等各種參數，對全球生物標誌市場的主要公司進行介紹。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、技術更新、市場擴張和行銷策略做出明智的決策。
《全球生物標記市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析全球生物標記市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 中非
- 北非

第9章競爭情勢

熱圖分析
市佔率分析
- Agilent Technologies, Inc.
- F.Hoffmann-La Roche Ltd.
- Acobiom
- Apis Assay Technologies Ltd.
- Eagle Biosciences, Inc.
- Beckman Coulter, Inc.
- PerkinElmer Inc.
- Biopanda Reagents Ltd
- Quanterix
- Secure Diagnostics Pvt. Ltd.
- BioVision Inc.
- Merck KGaA
- R&D Systems
- Life Diagnostics
- QuantaMatrix Inc.
- Nanjing Synthgene Medical Technology Co., Ltd
- LifeSpan BioSciences, Inc.
- Wako USA
- BioLegend, Inc.
- Abnova Corporation
- Abbexa
分析師意見

第10章

分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI1530

Biomarkers Market is estimated to be valued at USD 92.75 Bn in 2026 and is expected to reach USD 229.24 Bn by 2033, growing at a compound annual growth rate (CAGR) of 13.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 92.75 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	13.80%	2033 Value Projection:	USD 229.24 Bn

A biomarker is a quantifiable sign of a biological condition or state. In order to investigate typical biological processes, pathogenic processes, or pharmacologic reactions to a therapeutic intervention, biomarkers are frequently examined and studied utilizing blood, urine, or soft tissues. Numerous scientific disciplines employ biomarkers. There are 2 types of biomarkers actively used in the market, they are Biomarker test Kits and Biomarker Analyzer. A relatively new set of clinical toolsets organized by clinical applications includes biomarkers utilized in the medical industry.

Market Dynamics

Increasing product launch by market players is expected to drive the market growth over the forecast period. For instance, on April 19, 2021, Amgen Inc., a global biotechnology company that uses science and innovation to translate novel concepts and medical discoveries into treatments for patients with life-threatening illnesses, announced the launch of the Biomarker Assist program, which aims to provide access to biomarker testing for patients with metastatic (stage IV) non-small cell lung cancer (NSCLC). A crucial initial step in placing patients on the appropriate course of treatment is biomarker testing at the time of diagnosis. Eligible patients may receive discounts on biomarker testing through Biomarker Assist.

Furthermore, on February 28, 2022, an initiative program was launched by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium aims to find the most effective blood tests for assessing a protein that is crucial for the early detection of rare neurodegenerative illnesses. The Neurofilament as a Fluid Biomarker of Neuro degeneration in Familial Front temporal Degeneration (FTD) study will demonstrate that one or more blood tests for this protein, known as neurofilament, can be used to determine individuals at risk of Front temporal Degeneration (FTD) due to genetic and familial ties. This is a crucial first step in developing a trustworthy, affordable, and non-invasive method to more accurately predict Front temporal Degeneration (FTD). Also, those who are at threat can take part in clinical studies of novel specifics, eventually leading to the development of treatments.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global biomarkers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Acobiom, Apis Assay Technologies Ltd., Eagle Biosciences, Inc., Beckman Coulter, Inc., PerkinElmer Inc., Biopanda Reagents Ltd, Quanterix, Secure Diagnostics Pvt. Ltd., BioVision Inc., Merck KGaA, R&D Systems, Life Diagnostics, QuantaMatrix Inc., Nanjing Synthgene Medical Technology Co., Ltd, LifeSpan BioSciences, Inc., Wako USA, BioLegend, Inc., Abnova Corporation, and Abbexa
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global biomarkers market

Detailed Segmentation:

Global Biomarkers Market, By Product Type (Revenue, USD Bn, 2021 - 2033)
Biomarker Test Kits
Biomarker Analyzer
Global Biomarkers Market, By Application (Revenue, USD Bn, 2021 - 2033)
Diagnostic Biomarkers
Monitoring Biomarkers
Drug Discovery And Development
Predictive Biomarkers
Prognostic Biomarkers
Global Biomarkers Market, By Disease Indication (Revenue, USD Bn, 2021 - 2033)
Cancer
Cardiovascular Disease
Neurological Disorder
Infectious disease
Others (Immunological Disorder, and Autoimmune Disorders among others )
Global Biomarkers Market, By End User (Revenue, USD Bn, 2021 - 2033)
Hospitals
Research Laboratories
Diagnostic Laboratories
Research and Academic Institute
Global Biomarkers market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- By Country
  - U.S.
  - Canada
Latin America
- By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Country
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Region/Country
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Agilent Technologies, Inc. *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
F.Hoffmann-La Roche Ltd.
Acobiom
Apis Assay Technologies Ltd.
Eagle Biosciences, Inc.
Beckman Coulter, Inc.
PerkinElmer Inc.
Biopanda Reagents Ltd
Quanterix
Secure Diagnostics Pvt. Ltd.
BioVision Inc.
Merck KGaA
R&D Systems
Life Diagnostics
QuantaMatrix Inc.
Nanjing Synthgene Medical Technology Co. Ltd
LifeSpan BioSciences Inc
Wako USA,
BioLegend, Inc
Abnova Corporation
Abbexa

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Application
- Market Snapshot, By Disease Indication
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Key Developments
Industry Trends
Regulatory Scenario
Recent Product Approval/Launches
PEST Analysis
Porter's Analysis

4. Global Biomarkers Market, By Type, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Biomarker Test
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Biomarker Analyzers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

5. Global Biomarkers Market, By Application, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Diagnostic Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Monitoring Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Drug discovery and development
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Predictive Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Prognostic Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

6. Global Biomarkers Market, By Disease Indication, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Cardiovascular Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Neurological Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Infectious disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Others (Immunological Disorder, and Autoimmune Disorders among others )
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

7. Global Biomarkers Market, End User, 2021 - 2033 (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033(%)
- Y-o-Y Growth Analysis, For Regions, 2022 - 2033
- Regional Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021- 2033, (US$ Bn)
Research Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021- 2033, (US$ Bn)
Research and Academic Institute
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

8. Global Biomarkers Market, By Region, 2021 - 2033 (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033(%)
- Y-o-Y Growth Analysis, For Regions, 2022 - 2033
- Regional Trends
North America
- Market Size and Forecast, By Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By End User, 2021 - 2033 (US$ Bn)
  - U.S.
  - Canada
Latin America
- Market Size and Forecast, By Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By End User, 2021 - 2033 (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Size and Forecast, By Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By End User, 2021 - 2033 (US$ Bn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By End User, 2021 - 2033 (US$ Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By End User, 2021 - 2033 (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By End User, 2021 - 2033 (US$ Bn)
  - South Africa
  - Central Africa
  - North Africa

9. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Agilent Technologies, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- F.Hoffmann-La Roche Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Acobiom
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Apis Assay Technologies Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Eagle Biosciences, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Beckman Coulter, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- PerkinElmer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Biopanda Reagents Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Quanterix
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Secure Diagnostics Pvt. Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- BioVision Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merck KGaA
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- R&D Systems
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Life Diagnostics
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- QuantaMatrix Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Nanjing Synthgene Medical Technology Co., Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- LifeSpan BioSciences, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Wako USA
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- BioLegend, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Abnova Corporation
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Abbexa
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
Analyst Views